0001144204-18-062657.txt : 20181130 0001144204-18-062657.hdr.sgml : 20181130 20181130170545 ACCESSION NUMBER: 0001144204-18-062657 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181130 FILED AS OF DATE: 20181130 DATE AS OF CHANGE: 20181130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schor Chen CENTRAL INDEX KEY: 0001340875 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36641 FILM NUMBER: 181211873 MAIL ADDRESS: STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC. STREET 2: 4 MAGUIRE ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC. CENTRAL INDEX KEY: 0001137883 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 207273918 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 201-488-0460 MAIL ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC DATE OF NAME CHANGE: 20041122 FORMER COMPANY: FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC DATE OF NAME CHANGE: 20030827 FORMER COMPANY: FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC DATE OF NAME CHANGE: 20010409 4 1 tv507907_4.xml OWNERSHIP DOCUMENT X0306 4 2018-11-30 0 0001137883 BRAINSTORM CELL THERAPEUTICS INC. BCLI 0001340875 Schor Chen C/O BRAINSTORM CELL THERAPEUTICS INC. 1325 AVENUE OF AMERICAS, 28TH FLOOR NEW YORK NY 10019 1 0 0 0 Common Stock 2018-11-30 4 A 0 2000 0 A 125558 D Shares acquired are shares of restricted stock awarded on November 30, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. /s/ Thomas B. Rosedale (pursuant to Power of Attorney) 2018-11-30